# A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)

> **NCT01314872** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1395 (actual)

## Conditions studied

- Urinary Bladder, Overactive

## Interventions

- **DRUG:** Vibegron
- **DRUG:** Tolterodine ER
- **DRUG:** Placebo matching vibegron
- **DRUG:** Placebo matching tolterodine ER

## Key facts

- **NCT ID:** NCT01314872
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-31
- **Primary completion:** 2012-10-22
- **Final completion:** 2013-10-10
- **Target enrollment:** 1395 (ACTUAL)
- **Last updated:** 2019-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01314872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01314872, "A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01314872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*